Cagrilintide — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Acylation with a fatty-acid side chain extends its half-life into the weekly-dosing range. Investigated as a stand-alone weight-management agent and, more prominently, in fixed-combination with semaglutide ("CagriSema"). ## Mechanism of Action Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic β-cells. Cagrilintide acts at amylin and calcitonin receptors in the central nervous system to slow gastric emptying, reduce postprandial glucagon, and decrease appetite. Mechanism is complementary to GLP-1 agonism — combination regimens produce weight reductions beyond what either pathway achieves alone. ## Research Indications Obesity and overweight with metabolic comorbidities. Phase 2/3 trials have evaluated cagrilintide alone and combined with semaglutide. ## Reconstitution Typical 5 mg lyophilized vial: add **2.5 mL of bacteriostatic water**, swirl gently. Final concentration **2 mg/mL (2000 mcg/mL)** — each 0.05 mL (5 units on a U-100 insulin syringe) delivers 100 mcg. A 10 mg vial reconstituted with **2 mL** yields 5 mg/mL. ## Dosing Protocol (research literature) Published trials titrate **starting at 0.16 mg subcutaneously once weekly**, escalating every 4 weeks (0.30 → 0.60 → 1.2 → 2.4 mg weekly) to mitigate gastrointestinal effects. Maintenance dose in the obesity programs is **2.4 mg SC weekly**. When co-administered with semaglutide, both agents are escalated in parallel. ## Administration Subcutaneous injection into abdominal fat, thigh, or upper arm, rotating sites weekly. Inject on the same day each week. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **28 days**. Protect from light. Do not freeze. ## Side Effects Predominantly gastrointestinal — nausea, vomiting, decreased appetite, constipation — overlapping with GLP-1 agents. Most pronounced during dose escalation; mitigated by slow titration, hydration, and small meals. ## Contraindications Personal or family history of medullary thyroid carcinoma, MEN-2, history of pancreatitis, severe gastroparesis, pregnancy, and lactation. ## Monitoring Baseline weight, waist circumference, HbA1c, lipid panel, and basic metabolic panel. Re-measure at 12 and 24 weeks. Re-evaluate continuation against weight-reduction targets at 6 months. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.